Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ropivacaine · 1 trial · 1 indication
The primary outcomes will be the onset time, onset of surgical block, and duration of analgesia.
| Arm | Type | Description |
|---|---|---|
| Group 1 | ACTIVE_COMPARATOR | combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence; |
| Group 2 | ACTIVE_COMPARATOR | sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepivacaine, syringe 2 containing 15 mL of 0.5% ropivacaine (total, 30 mL); syringe 2 was injected with a 90-sec delay after injection of syringe 1. |
| Name | Type | Description |
|---|---|---|
| Ropivacaine | DRUG | ropivacaine (15 ml). |
| Mepivacaine | DRUG | One syringe will contain mepivacaine (15 ml) |
Inclusion Criteria: * Patients undergoing upper extremity procedures suitable for supraclavicular anesthesia, including but not limited to oHand surgery oForearm surgery oElbow surgery * Age between 18 and 70 years Exclusion Criteria: * Contraindications to supraclavicular block * Coagulopathy...